Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
3,960
datasets available to search
ShareScore release 0.9.0
Dataset results
3,960 results for “lung patient”
Gemcitabine Hydrochloride and Carboplatin With or Without MK-0646 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT00951444. IPD Sharing: Not stated. Countries: 0. Publications: 0.
ZD0473 in Treating Patients With Progressive or Relapsed Non-Small Lung Cancer
ClinicalTrials.gov study NCT00021008. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Liposomal SN-38 in Treating Patients With Small Cell Lung Cancer
ClinicalTrials.gov study NCT00104754. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Gefitinib and Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT00268255. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Multimodal single-cell and spatial profiling reveals altered T cell-mediated immunity and B-cell follicular architecture in non-metastatic lymph nodes of patients with aggressive non-small cell lung c
GEO Series GSE316782. Homo sapiens. 18 samples. Type: Expression profiling by high throughput sequencing; Other.
CD39 Identifies Tumor-Reactive CD8 T cells in Patients With Lung Cancer [FB]
GEO Series GSE218259. Homo sapiens. 2 samples. Type: Other.
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial (Lung patients)
GEO Series GSE171702. Homo sapiens. 32 samples. Type: Expression profiling by array.
Next Generation Sequencing Quantitative Analysis of RA-UIP, IPF-UIP, and Non-UIP Patient Lung Biopsy Transcriptomes
GEO Series GSE199152. Homo sapiens. 27 samples. Type: Expression profiling by high throughput sequencing.
Expression data from lung resident mesenchymal stem cells from idiopathic pulmonary fibrosis patients and control subjects
GEO Series GSE240470. Homo sapiens. 8 samples. Type: Expression profiling by array.
Proteogenomic Characterization Reveals Estrogen Signaling as a Target for Never-Smoker Lung Adenocarcinoma Patients without EGFR or ALK Alterations [RNA-seq]
GEO Series GSE256091. Homo sapiens. 141 samples. Type: Expression profiling by high throughput sequencing.
The gene expression profiles of EGFR-mutant SCLC cell lines derived from lung adenocarcinoma patients after failed EGFR-TKI treatment.
GEO Series GSE122698. Homo sapiens. 12 samples. Type: Expression profiling by array.
Dataset related to article "Cost-effectiveness of second-line diagnostic investigations in patients included in the DANTE trial: a randomized controlled trial of lung cancer screening with low-dose computed tomography."
<p>AIM:</p> <p>The aim of this study was to analyze the economic efficiency of second-line diagnostic investigations in patients with undetermined lung nodules.</p> <p>PARTICIPANTS AND METHODS:</p> <p>A retrospective review of all surgical cases included in the DANTE trial from 2001 to 2006 for lung cancer screening was performed. Overall, 217 patients and 261 lung nodules were analyzed. The cohort was divided into patients investigated with PET and/or computed tomography (CT)-guided biopsy (PET-CTB protocol; N=100), compared with those assessed with serial low-dose CT scans (standard protocol; N=161). Outpatient's and inpatient's costs were expressed in euros and derived from the Italian National Health Service. Ineffective costs were defined as the cost of procedures that lead to avoidable surgical intervention.</p> <p>RESULTS:</p> <p>The diagnostic accuracy of the two protocols was 91% for the standard (sensitivity 100%, specificity 91%, positive predictive value 26%, and negative predictive value 100%) and 90% for the PET-CTB protocol (sensitivity 98%, specificity 81%, positive predictive value 85%, and negative predictive value 97%). Average costs for outpatient's diagnostics were 694 and 1.462 euros, respectively, for the standard and PET-CTB protocol. Average inpatient's costs for both protocols were 12.121 euros. The two protocols showed comparable effectiveness in terms of outpatient's costs (94 and 90%, respectively; P=0.252). Inpatient's costs were effective in 36% of cases monitored according to the standard protocol compared with 85% of patients investigated with PET-CTB protocol. Ineffective costs corresponded to 64 and 15%, respectively (P<0.0001).</p> <p>CONCLUSION:</p> <p>Despite a higher average cost for outpatient's diagnostics, the implementation of PET imaging with or without CT-guided needle biopsy in the workup of suspicious lung nodules results in reduced unnecessary harm and costs related to inpatient's procedures.</p>
Procalcitonin and lung ultrasonography point-ofcare testing to decide on antibiotic prescription in patients with lower respiratory tract infection at primary care level: pragmatic cluster randomized trial
<p>Dataset of the ULTRAPRO cluster-randomized clinical trial. </p>
Dataset related to article: "Therapist Driven Rehabilitation Protocol for Patients with Chronic Heart and Lung Diseases: A Real-Life Study"
<p>We provide the raw data used for the following article:</p> <ul> <li>Simonelli C, Vitacca M, Ambrosino N, Scalvini S, Rivadossi F, Saleri M, Fokom AG, Speltoni I, Ghirardi R, Paneroni M.<br> <em>Therapist Driven Rehabilitation Protocol for Patients with Chronic Heart and Lung Diseases: A Real-Life Study</em>.<br> "Int J Environ Res Public Health". 2020 Feb 5;17(3):1016. doi: 10.3390/ijerph17031016. PMID: 32033505; PMCID: PMC7037983.</li> </ul> <p><br> <strong>Abstract</strong><br> Therapist driven protocols may help to tailor rehabilitation programs to individual patients. We aimed to test the feasibility, safety, and clinical usefulness of a therapist driven protocol for rehabilitation including exercise training of patients with heart or lung diseases. An internal audit elaborated the Cardio-Respiratory Exercise Maugeri Algorithm (CREMA) based on: (a) standardized baseline assessments, (b) decision-making pathways, and (c) frequency/intensity/time/type (FITT) of prescription for each exercise. Outpatients (<em>n</em> = 620) with chronic heart disease (CHD), recent myocardial revascularization (REVASC), chronic airway (Obstructive), and restrictive lung (Restrictive) diseases underwent exercise training according to CREMA during 4 years. Peripheral muscle strengthening was the most prescribed exercise (83.6%), while arm endurance training was the least frequently (0.75%). Exercise prescription varied widely among the disease groups (interval training 19-47%, balance 35-49%, lower limb muscle training 6-15%). After training, REVASC patients were the best improvers in the 6 min walking distance (+48.7 (56.1) m), maximal inspiratory pressure (+9.6 (15.4) cmH<sub>2</sub>O), and daily steps (+1087.2 (3297.1) n/day). Quadriceps and biceps strength, maximal expiratory pressure, and balance improved in all groups, without significant differences. Minor side effects were observed in 11.2% of the patients. The CREMA therapist driven protocol was feasible, safe, and useful for prescribing tailored training programs. Exercise prescriptions and training response differed among diseases.</p>
Lung Ultrasound in Patients With SARS-COV-2 Pneumonia Correlations With Chest Computed Tomography, Respiratory Impairment, and Inflammatory Cascade
<p>Objectives—Lung ultrasound (LUS) might be comparable to chest computed tomography (CT) in detecting parenchymal and pleural pathology, and in monitoring interstitial lung disease. We aimed to describe LUS characteristics of patients during the hospitalization for COVID-19 pneumonia, and to compare the extent of lung involvement at LUS and chest-CT with inflammatory response and the severity of respiration impairment.<br> Methods—During a 2-week period, we performed LUS and chest CT in hospitalized patients affected by COVID-19 pneumonia. Dosages of high sensitivity C-reactive protein (HS-CRP), D-dimer, and interleukin-6 (IL-6) were also obtained. The index of lung function (P/F ratio) was calculated from the blood gas test. LUS and CT scoring were assessed using previously validated scores. <br> Results—Twenty-six consecutive patients (3 women) underwent LUS 34 - 14 days from the early symptoms. Among them, 21 underwent CT on the same day of LUS. A fair association was found between LUS and CT scores (R = 0.45, P = .049), which became stronger if the B-lines score on LUS was not considered (R = 0.57, P = .024). LUS B-lines score correlated with IL-6 levels (R = 0.75, P = 0.011), and the number of involved lung segments detected by LUS correlated with the P/F ratio (R = 0.60, P = .019) but not with HS-CRP and D-Dimer levels. No correlations were found between CT scores and inflammations markers or P/F.<br> Conclusion—In patients with COVID-19 pneumonia, LUS was correlated with both the extent of the inflammatory response and the P/F ratio. </p>
Detecting small cell transformation in patients with advanced EGFR mutant lung adenocarcinoma through epigenomic cfDNA profiling
GEO Series GSE269746. Homo sapiens. 128 samples. Type: Methylation profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing.
Circulating tumor cell analysis from stage III lung cancer patients
GEO Series GSE249262. Homo sapiens. 76 samples. Type: Expression profiling by array.
Expression data in lung tissue from moderate COPD patients, healthy smokers and nonsmokers
GEO Series GSE37768. Homo sapiens. 38 samples. Type: Expression profiling by array.
Dataset related to article "Stereotactic Body Radiation Therapy for Lung Metastases From Sarcoma in Oligometastatic Patients: A Phase 2 Study"
<p>This record contains raw data related to article "Stereotactic Body Radiation Therapy for Lung Metastases From Sarcoma in Oligometastatic Patients: A Phase 2 Study"</p><p>Abstract</p><p><strong>Purpose: </strong>The lung is the most frequent site of metastasis in patients with sarcoma. Pulmonary metastasectomy is the most common treatment performed. Stereotactic body radiation therapy (SBRT) has proven to be a potential alternative to resection. This prospective phase 2 study aimed to assess the role of SBRT for patients with lung metastases.</p><p><strong>Methods and materials: </strong>Adult patients with up to 4 lung metastases (LMs) ≤5 cm in diameter and unsuitable for surgery were included. Dose prescription was based on site and size: 30 Gy/1 fraction for peripheral lesions ≤10 mm, 60 Gy/3 fractions for peripheral lesions 11 to 20 mm, 48 Gy/4 fractions for peripheral lesions >20 mm, and 60 Gy/8 fractions for central lesions. The primary endpoint was the proportion of treated lesions free from progression at 12 months. Secondary endpoints were disease-free survival (DFS), overall survival (OS), and toxicity.</p><p><strong>Results: </strong>Between March 2015 and December 2020, 44 patients with a total of 71 LMs were enrolled. Twelve-month local control was 98.5% ± 1.4%, reaching the primary aim; the median DFS time was 12 months (95% CI, 8-16 months), and the 1-, 2-, 3-, 4-, and 5-year PFS rates were 50% ± 7.5%, 19.5% ± 6.6%, 11.7% ± 5.8%, 11.7% ± 5.8%, and 11.7% ± 5.8%, respectively. The median OS time was 49 months (95% CI, 24-49 months), and the 1-, 2-, 3-, 4-, and 5-year OS rates were 88.6% ± 4.7%, 66.7 ± 7.6%, 56.8% ± 8.4%, 53.0% ± 8.6%, and 48.2% ± 9.1%, respectively. Prognostic factors recorded as significantly affecting survival were age, grade of primary sarcoma, interval time from diagnosis to occurrence of LMs, and number of LMs. No severe pulmonary toxicity (grade 3-4) occurred.</p><p><strong>Conclusions: </strong>The study found a local control of LMs in almost all patients treated, with negligible toxicity. Survival was also highly satisfactory. Well-designed randomized trials comparing surgery with SBRT for patients with metastatic lung sarcoma are needed to confirm these preliminary data</p>
Intrinsic gene profiles in patients with non–small cell lung cancer
<p><strong>Intrinsic gene profiles in patients with non–small cell lung cancer</strong></p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.